• Mira Pharmaceuticals received a Nasdaq notice for failing to meet the $1 minimum bid price rule after 30 straight business days below $1.
• Shares remain listed on the Nasdaq Capital Market under MIRA with no immediate impact on trading.
• Compliance deadline set for Jan. 25, 2027; stock must close at or above $1 for 10 consecutive business days.
• Failure to regain compliance could trigger a delisting notice; a reverse stock split remains an option to cure the deficiency.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mira Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-26-035665), on July 31, 2026, and is solely responsible for the information contained therein.